ClinicalTrials.gg
RecruitingNCT07014371Updated Oct 14, 2026

Alternate-Day vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)

An interventional study of Ferrous Fumarate Oral Tablet in Iron Deficiency Anemia Treatment, sponsored by Phramongkutklao College of Medicine and Hospital. Recruiting at 1 site in Thailand. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Phramongkutklao College of Medicine and Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 14, 2026Eligibility revisedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency — 2 open to participants now, 2 under way, none of them phase 3. ferrous fumarate · Anemia, Iron-Deficiency.

Planned enrollment
8th of 12
60 · median 74
Started
2025
the only one that year
No phase
6 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Phramongkutklao College of Medicine and Hospital

Among the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is one of 6 with no phase, and was the 12th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

2 of the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ferrous fumarate

ferrous fumarate: first FDA approval 1978 (NORMINEST FE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the effectiveness and tolerability of two different oral iron regimens in adults with iron deficiency anemia (IDA). The main questions it aims to answer are:

Is alternate-day oral iron supplementation as effective as once-daily dosing in improving hemoglobin levels?

What are the side effects associated with each dosing regimen?

Researchers will compare once-daily vs. alternate-day oral ferrous fumarate to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response, with fewer adverse effects.

Participants will:

Be randomly assigned to take ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks

Undergo blood tests and clinical assessments at baseline, Week 4, and Week 8

Report any side effects and bring remaining pills to evaluate medication adherence

This is a multicenter, randomized, open-label, non-inferiority trial conducted in adults aged 20 years or older with IDA.

03

Conditions studied

  • Iron Deficiency Anemia Treatment

Keywords

  • Iron deficiency anemia
  • Ferrous fumarate
  • Alternate day dosing
  • Hemoglobin
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥20 years diagnosed with iron deficiency anemia, defined as: (Hb) \<13 g/dL in males or \<12 g/dL in females, and ferritin \<50 ng/mL or transferrin saturation (TSAT) \<20%.
  • No iron supplementation within the past 3 months.

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability (e.g., acute bleeding or hypotension).
  • Severe heart failure ( [NYHA] Class III-IV) or other active cardiac diseases.
  • Active or history of cancer within the past 3 years (except non-melanoma skin cancer).
  • Pregnancy or breastfeeding.
  • Chronic liver disease including cirrhosis ( class B or C).
  • Chronic kidney disease (estimated [eGFR] \<60 mL/min/1.73 m²).
  • thalassemia or hemoglobinopathies.
  • Ongoing infection or chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease).
  • Malabsorption disorders (e.g., history of bariatric surgery).
  • Red blood cell transfusion within the past 3 months.

Withdrawal Criteria

  • The participant requests to withdraw from the research study.
  • level decreases by 1 g/dL or more compared to baseline at Week 4 or Week 8.
  • Blood hemoglobin level increases by less than 1 g/dL following the evaluation at Week 4 or Week 8, which is considered treatment failure.
  • Occurrence of severe complications, such as symptomatic anemia or circulatory collapse, requiring intravenous iron therapy or blood transfusion.
  • Occurrence of severe adverse events that render the participant unable to tolerate oral iron, even after dose reduction.

Treatment Failure

- Increase in hemoglobin level of \< 1 g/dL at Week 4 or Week 8 compared with baseline.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Once-Daily Dosing Group

    Participants will receive ferrous fumarate 200 mg, taken orally once daily for 8 weeks. This arm represents the standard dosing regimen for treating iron deficiency anemia (IDA). Participants will be monitored at baseline, Week 4, and Week 8 for blood counts, iron parameters, and adverse effects. Medication adherence will be assessed using pill counts.

    Drug: Ferrous Fumarate Oral Tablet

  • Experimental
    Alternate-Day Dosing Group

    Participants will receive ferrous fumarate 400 mg (two 200 mg tablets), taken orally on alternate days for 8 weeks. This dosing strategy is being evaluated for improved iron absorption and fewer gastrointestinal side effects compared to daily dosing. Participants will be monitored at baseline, Week 4, and Week 8 for blood counts, iron parameters, and adverse effects. Medication adherence will be assessed using pill counts.

    Drug: Ferrous Fumarate Oral Tablet

Interventions

  • DrugFerrous fumarateStudies of Ferrous fumarateFerrous fumarate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferrous fumarate oral tablet 200 mg is an iron supplement used for the treatment of iron deficiency anemia (IDA). In this study, it is administered as either one tablet daily (OD group) or two tablets on alternate days (AD group), with a treatment duration of 8 weeks. The goal is to compare the efficacy and tolerability of alternate-day dosing versus standard once-daily dosing.

    Also known as: Ferrous Fumarate 200 mg tablet, Oral iron supplement

06

What researchers measure

Primary outcomes

  1. Hemoglobin Level at Week 8 After Oral Iron Supplementation

    Hemoglobin concentration (g/dL) measured at Week 8 following oral ferrous fumarate supplementation. Participants are stratified by sex and baseline Hb level. Comparison between once-daily and alternate-day dosing groups will be analyzed using a linear mixed-effects model.

    Time frame: 8 weeks

Secondary outcomes

  1. Change in Reticulocyte Count at Weeks 4 and 8

    Mean change in reticulocyte count (%) from baseline to Week 4 and Week 8.

    Time frame: 4 and 8 weeks

  2. Change in Serum Ferritin at Weeks 4 and 8

    Mean change in serum ferritin concentration (ng/mL) from baseline to Week 4 and Week 8.

    Time frame: 4 and 8 weeks

  3. Adverse Effects of Ferrous Fumarate

    Incidence and type of adverse effects experienced by participants during treatment with ferrous fumarate oral tablets.

    Time frame: During the 8-week treatment period

07

Study locations

1 of 1 sites recruiting
  • Phramongkutklao Hospital
    Bangkok, 10400, Thailand
    Recruiting
    • Tanapun Thamgrang, Doctor of Medicine · Contacttanapun.tham@pcm.ac.th · 66859930142
    • Aticha Kraiput, Doctor of Medicine · Contactaticha.kr18@gmail.com · 66862849871
    • Aticha Kraiput, Doctor of Medicine · Principal investigator
    • Tanapun Thamgrang, Doctor of Medicine · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to institutional policy and privacy concerns. Only aggregate data may be shared upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 30 months is above that.

Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jun 11, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
114→60
Sep 30, 2026
Eligibility
5 exclusion criteria added, 4 removed
What changed in the criteria
Exclusion criteria
  • RemovedWithdrawal of informed consent.
  • RemovedSevere adverse events requiring permanent discontinuation of study medication.
  • RemovedInvestigator's judgment that continued participation poses a safety risk.
  • RemovedNon-adherence to study medication (compliance < 75%).
  • AddedThe participant requests to withdraw from the research study.
  • AddedHemoglobin level decreases by 1 g/dL or more compared to baseline at Week 4 or Week 8.
  • AddedBlood hemoglobin level increases by less than 1 g/dL following the evaluation at Week 4 or Week 8, which is considered treatment failure.
  • AddedOccurrence of severe complications, such as symptomatic anemia or circulatory collapse, requiring intravenous iron therapy or blood transfusion.
  • AddedOccurrence of severe adverse events that render the participant unable to tolerate oral iron, even after dose reduction.
Oct 14, 2026
Title
AlternativeAlternate-Day vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)
Sep 30, 2026
Show all 2 updates
  1. Oct 14, 2026
    Eligibility 5 exclusion criteria added, 4 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedWithdrawal of informed consent.
    • RemovedSevere adverse events requiring permanent discontinuation of study medication.
    • RemovedInvestigator's judgment that continued participation poses a safety risk.
    • RemovedNon-adherence to study medication (compliance < 75%).
    • AddedThe participant requests to withdraw from the research study.
    • AddedHemoglobin level decreases by 1 g/dL or more compared to baseline at Week 4 or Week 8.
    • AddedBlood hemoglobin level increases by less than 1 g/dL following the evaluation at Week 4 or Week 8, which is considered treatment failure.
    • AddedOccurrence of severe complications, such as symptomatic anemia or circulatory collapse, requiring intravenous iron therapy or blood transfusion.
    • AddedOccurrence of severe adverse events that render the participant unable to tolerate oral iron, even after dose reduction.
    + 1 other change: verification date
  2. Sep 30, 2026
    Enrollment 114→60
    Title AlternativeAlternate-Day vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07014371
Lead sponsor
Phramongkutklao College of Medicine and Hospital
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 9, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Tanapun Thamgrang, Doctor of Medicine
Contact
tanapun.tham@pcm.ac.th
66859930142
Aticha Kraiput, Doctor of Medicine
Contact
aticha.kr18@gmail.com
66862849871

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferrous fumarate

Start the discussion